Help your customers to kick the habit for good with Nicotinell

Nicotinell product range

60% greater chance of quitting1 with combination therapy vs single product Nicotine Replacement Therapy (NRT) treatment

A range of products to help provide effective relief from nicotine cravings.

Call now to order

Runners

NRT allows patients to decrease their therapeutic nicotine intake, as both the physical and behavioural dependency is reduced2-4

Public Health England recommends combining NHS local stop smoking services with the use of smoking cessation aids including NRT to increase success rates by up to four times5.

How NRT works

Many smokers trying to quit experience withdrawal symptoms and cravings that may be hard to overcome with willpower alone.

NRT products deliver lower levels of therapeutic nicotine without the 7000 other chemicals found in tobacco smoke.

  • Approximately 70-90% of smokers say that withdrawal symptoms and cravings are the reason they do not quit smoking. Nicotine replacement therapy (NRT) can help relieve physical withdrawal symptoms6.
  • NRT addresses your customers’ physical need to smoke using consistent, controlled therapeutic nicotine to wean them down gradually7-9.
  • By reducing the physical symptoms from smoking cessation, NRT enables the customer to focus more on the emotional aspect of quitting6.
  • NRT helps manage withdrawal symptoms, which manifest within the first 1-2 days, peak within the first week and gradually dissipate over 3-4 weeks10.
  • Cravings are often psychologically motivated and can last for months. The use of behavioural programmes in conjunction with NRT can improve success11.
Relieves 5 withdrawal symptoms of quitting image

Nicotinell products help relieve the 5 withdrawal symptoms of quitting

Nicotinell can make it easier for your customers to stop smoking because it helps relieve their cravings.

Order now

Recommend Nicotinell to help your customers and patients kick the habit for good

Nicotinell gum range shot

Nicotinell Medicated Chewing Gum

Rapid relief from sudden cravings.

Nicotinell gum is available in two flavours, mint or fruit, to satisfy varying tastes.  Easy to chew with a crispy coating just like normal gum.

Available in 2 mg and 4 mg, in pack sizes of 96 and 204 pieces.

Nicotinell lozenges pack-shot

Nicotinell Compressed Lozenge

Starts to work in minutes; provides long-lasting craving relief.

Nicotinell lozenges help customers stop smoking with a fresh, minty taste. Customers can use the lozenges discreetly to help them stop smoking at work or on other occasions where they cannot chew gum.

Available in 1mg and 2mg strength, in pack sizes of 12, 96, 144, 204.

Nicotinell patch pack-shot

Nicotinell 24 Hour Patch

24 hour nicotine craving relief.

Nicotinell patches contain enough nicotine protection for 24 hours when customers stop smoking.

By using the patches for 24 hours, customers will have nicotine in their blood when they wake up, so they’ll be ready to face the morning cravings more easily.

Nicotinell patches are available in three strengths: 7 mg, 14 mg and 21 mg in pack sizes of 10, 20 and 30 patches.

Step 1 is in pack size of 7s and 21s

Step 2 and 3 only pack size of 7s

Nicotinell product range details

  • Nicotinell® Fruit/ Mint 2 mg/4 mg Medicated Chewing Gum (nicotine)

    Indications: To aid smokers wishing to quit or reduce prior to quitting, including in pregnant and lactating women. Use in conjunction with behavioural support.

    Dosage and administration: Adults: 1 gum chewed when urge to smoke. 8-12 gums/day, up to max 25 gums/day (2 mg) or 15 gums/day (4 mg). < 20 cigarettes/day: 2 mg preferable, 20-30 cigarettes/day: 2 mg or 4 mg, > 30 cigarettes/day: 4 mg preferable. Use 4 mg if previous failed quit using NRT. Withdraw gradually after 3 months; discontinue when 1-2 gums daily. Avoid acidic drinks 15 minutes prior to dosing. Adolescents aged 12-18 years: As adults but review if need > 12 weeks.

    Contraindications: Hypersensitivity to ingredients. Non smokers.

    Precautions: In dependent smokers hospitalised as a result of recent myocardial infarction, unstable or worsening angina pectoris, severe cardiac arrhythmias, uncontrolled hypertension, or recent cerebrovascular incident who are haemodynamically unstable, consider only if non pharmacological intervention fails. Diabetes mellitus, upper GI tract inflammation, moderate/severe hepatic impairment and/or severe renal impairment, uncontrolled hyperthyroidism or pheochromocytoma. Denture wearers/TMJ problems. Fructose intolerance.

    Side effects: See SPC for full details. Headache, dizziness, salivary hypersecretion, stomatitis, oral pain, pharyngolaryngeal pain, hiccups, nausea, vomiting, dyspepsia, flatulence, jaw muscle ache. Hypersensitivity, angioneurotic oedema and anaphylactic reactions.

    Legal category: GSL.

    Presentation and NHS cost: 2 mg 96 £12.33, 2mg 204 £21.24. 4 mg 96 £15.31. Fruit 2 mg/4 mg PL 44673/0122 & 0123; Mint 2 mg/4 mg PL 44673/0126 & 0127.

    PL holder: GlaxoSmithKline Consumer Healthcare (UK) Trading Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS, U.K.

    Date of preparation: September 2019.

  • Nicotinell® Mint 1 mg/2 mg Compressed Lozenges (nicotine)

    Indications: Smoking cessation or temporary smoking reduction in smokers motivated to quit. Use in conjunction with behavioural support.

    Dosage and administration: Adults: Cessation

    Nicotinell Patch plus Lozenge (when Lozenge alone has failed in those smoking > 20 cigs/day) use > 4 x 1mg Lozenges/day (max 15) for 6 -12 weeks then reduce. Nicotinell Lozenge alone < 20 cigs/day: 1mg; > 30 cigs/day: 2mg. 20 - 30 cigs/day: 1mg or 2 mg. 1 Lozenge every 1 - 2 hours, usually 8 -12/day. Max 30mg/day. Reduce after 3 months. Stop at 6 months. Smoking reduction: Replace cigarettes gradually with Lozenge. Make quit attempt within 4 months. Avoid acidic drinks 15 mins before dosing. Children and adolescents <18 years: Only on physician advice.

    Contraindications: Non smokers. Hypersensitivity to ingredients.

    Precautions: In dependent smokers with recent myocardial infarction, unstable or worsening angina, severe cardiac arrhythmias, uncontrolled hypertension, or recent cerebrovascular incident consider only if non pharmacological intervention fails.  Hypertension, stable angina pectoris, cerebrovascular disease, occlusive peripheral arterial disease, heart failure, diabetes mellitus, hyperthyroidism or pheochromocytoma, moderate/severe hepatic or severe renal impairment. May exacerbate symptoms in upper GI inflammation. Phenylketonuria, fructose intolerance.

    Pregnancy: Use only if failed without NRT.

    Side effects: See SPC for full details. Dizziness, headache, nausea, flatulence, hiccups, gastritis, dry mouth, stomatitis, oesophagitis. Hypersensitivity, anaphylactic reactions, angioneurotic oedema.

    Legal category: GSL.

    Presentation and NHS cost: 1 mg PL 44673/0118: 12 £2.08, 96 £13.61, 144 £17.14, 204 £19.05. 2 mg PL 44673/0119: 96 £15.83, 144 £20.00, 204 £22.29.

    PL holder:  GlaxoSmithKline Consumer Healthcare (UK) Trading Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS, U.K.

    Date of preparation: September 2019.

  • Nicotinell TTS 10 (7 mg/24 hrs), Nicotinell TTS 20 (14 mg/24 hrs) and Nicotinell TTS 30 (21 mg/24 hrs) patches (nicotine)

    Indications: To aid smokers wishing to quit or reduce prior to quitting, including in pregnant and lactating women. Use in conjunction with behavioural support.

    Dosage and administration:  Adults and children over 12 years: Apply one patch daily, reducing strength every 3-4 weeks. ≥ 20 cigarettes/day: start with TTS 30, < 20 cigarettes/day: start with TTS 20. Pregnancy remove patch at bedtime.

    Contraindications: Non/occasional smokers, hypersensitivity to nicotine/patch components, skin diseases preventing patch application.

    Precautions: Skin disease, diabetes, moderate/severe hepatic impairment or severe renal impairment, peptic ulcer, uncontrolled hyperthyroidism or pheochromocytoma.  Discontinue if severe/persistent skin reaction. Smokers hospitalised for recent myocardial infarction, unstable or worsening angina pectoris, severe cardiac arrhythmias, uncontrolled hypertension, or recent cerebrovascular incident and who are haemodynamically unstable, consider patch only if non pharmacological intervention fails. 

    Side effects: See SPC for full details. Application site reactions, agitation, anxiety, nervousness, insomnia, abnormal dreams, headache, dizziness, motor dysfunction, cough, nausea, abdominal pain, dyspepsia, myalgia, arthritis. Allergic reactions including urticaria, rash, pruritus, angioedema and anaphylactoid reaction. 

    Legal category: GSL.

    Presentation and NHS cost: TTS 10: 7 day £13.61. PL 44673/0128. TTS 20: 7 day £14.04. PL 44673/0129. TTS 30: 7 day £14.89, 21 day £36.59 PL 44673/0130.

    PL holder: GlaxoSmithKline Consumer Healthcare (UK) Trading Limited, 980 Great West Road, Brentford, Middlesex, TW8 9GS, U.K.

    Date of preparation: September 2019.

Help your patients quit smoking for good with Nicotinell

Patient resources icon

Patient care resources

Download resources for your patients

Find out more

Learning lab icon

Learning Lab

Access educational resources to build your knowledge and skills

Access resources

Products icon

Order products

Place your order today

Order now